Market Intelligence, Clinical Progress, and High-Purity Reagents for Mineralocorticoid Receptor (MR) Therapeutic Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for NR3C2 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | NR3C2 LBD & Full-Length Recombinant Protein / Mutant Panel High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. Theoretical MW confirmed. |
View NR3C2 Products |
| Gene Delivery | NR3C2 Promise-ORF / Lentivirus Full-length ORF for stable reporter cell line construction. |
View NR3C2 Products |
| Benchmark Ab | Anti-NR3C2 Recombinant Rabbit mAb (ChIP / WB / IF Grade) Sequence Verified. Positive control for target engagement. |
View NR3C2 Products |
| Validator | NR3C2 siRNA Set (3 unique sequences) For knockdown and specificity verification in cell-based assays. |
View NR3C2 Products |
| Related Target: NR3C1 | Glucocorticoid Receptor (GR) Critical off-target for selectivity counter-screening in NR3C2 programs. |
View NR3C1 Products |
| Related Target: HSD11B2 | 11β-Hydroxysteroid Dehydrogenase Type 2 Modulates cortisol access to MR; synergistic cardiorenal pathway target. |
View HSD11B2 Products |
| Related Target: CYP11B2 | Aldosterone Synthase Upstream RAAS enzyme controlling ligand availability for NR3C2 activation. |
View CYP11B2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| NR3C1 (GR) selectivity counter-screening | Human NR3C1 LBD protein available with same >95% purity and sequence verification for direct head-to-head binding assays. |
| Nuclear receptor off-target panel (AR, PR, ER) | Homologous nuclear receptor panel strictly sequence-verified; ideal for TR-FRET/FP competition assays. |
| Lack of cellular reporter controls | NR3C2 lentiviral ORF for stable luciferase-reporter cell line generation; endotoxin-controlled prep. |
| False positives / Target confirmation | Validated siRNA and ChIP-grade antibody included for genetic knockdown and chromatin engagement verification. |
| Mutant / resistance mechanism studies | NR3C2 mutant recombinant proteins (e.g., S810L gain-of-function) with theoretical MW and high purity for structural biology. |
Live NR3C2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for NR3C2-targeted therapeutics is intensifying, with major players shifting focus from legacy steroidal antagonists (e.g., spironolactone) to next-generation non-steroidal mineralocorticoid receptor antagonists (nsMRAs). As first-generation therapies such as finerenone (Bayer) establish a foothold in chronic kidney disease and heart failure, the next wave of R&D is targeting tissue-selective modulation, improved safety margins (hyperkalemia mitigation), PROTAC-mediated degradation, and combinations with SGLT2 inhibitors for synergistic cardiovascular benefits. Emerging interest also includes CNS-penetrant modalities for neurodegenerative and psychiatric indications.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Non-steroidal Small Molecule MRA | Bayer, Daiichi Sankyo, KBP Biosciences | CKD (T2D), Hypertension, Heart Failure | Selectivity Assay (Need NR3C2 vs NR3C1/AR/WT panel proteins) |
| Steroidal MRA | Generic / Legacy | Primary Aldosteronism, HFrEF | Off-target profiling (Need AR/PR counter-screening antigens) |
| PROTAC / Degrader | Academic / Early Biotech | Resistant Cardiorenal Disease | Full-length & Mutant NR3C2 proteins for ternary complex formation |
| Gene Therapy / siRNA | Preclinical | Tissue-specific NR3C2 silencing | High-titer Lentivirus and validated siRNA for stable knockdown |
Key Mutations and Functional Domains
NR3C2 (UniProt P08235) contains a ligand-binding domain (NR LBD) critical for drug development. Key mutations include:
- S810L: Gain-of-function mutation causing constitutive activation, linked to early-onset hypertension exacerbated by pregnancy.
- rs5522 (I180V): Decreased mineralocorticoid receptor activity, associated with altered aldosterone response.
- Somatic mutation in colorectal cancer: Identified in a colorectal cancer sample (UniProt VAR_036063).
- Other variants: Changed response curve to aldosterone (UniProt VAR_015625).
These mutations underscore the need for mutant recombinant proteins in selectivity and resistance studies.